[Successful symptomatic treatment of epidermodysplasia verruciformis with imiquimod 5% cream]

Hautarzt. 2010 Dec;61(12):1052-5. doi: 10.1007/s00105-010-1998-4.
[Article in German]

Abstract

A 19-year-old patient presented with epidermodysplasia verruciformis (EV). In this genodermatosis, pathogenetic factors such as infection by human papilloma viruses as well as sun exposure are considered responsible for the malignant transformation of EV lesions to skin cancer within decades. So far, several therapeutic strategies have been unsatisfactory. In our case HPV 5b was detected and the associated skin lesions were successfully treated with imiquimod 5% cream.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Adjuvants, Immunologic / adverse effects
  • Administration, Topical
  • Aminoquinolines / administration & dosage*
  • Aminoquinolines / adverse effects
  • Biopsy
  • Consanguinity
  • DNA Probes, HPV
  • Drug Administration Schedule
  • Drug Eruptions / etiology
  • Epidermodysplasia Verruciformis / diagnosis
  • Epidermodysplasia Verruciformis / drug therapy*
  • Epidermodysplasia Verruciformis / genetics
  • Epidermodysplasia Verruciformis / pathology
  • Facial Dermatoses / diagnosis
  • Facial Dermatoses / drug therapy*
  • Facial Dermatoses / genetics
  • Facial Dermatoses / pathology
  • Humans
  • Imiquimod
  • Male
  • Oligonucleotide Array Sequence Analysis
  • Papillomavirus Infections / complications
  • Papillomavirus Infections / diagnosis
  • Skin / pathology

Substances

  • Adjuvants, Immunologic
  • Aminoquinolines
  • DNA Probes, HPV
  • Imiquimod